Dr. Xiaoxiang Chen has led the successful clinical development and registration into the China market of more than 20 global innovative products across multiple therapeutic areas.

Xiaoxiang has been the Chief Development Officer for Harbour Biomed since Jan 2019, in full charge of product development process from pre-clinical development, CMC, clinical development and regulatory affair until BLA approval.  Before joining Harbour BioMed in Nov of 2017, in his role as Medical Lead of Emerging Markets at Boehringer Ingelheim, Dr. Chen had overall medical responsibilities, including clinical development, regulatory affair, medical affair, …in more than 80 countries and regions, including China, Taiwan, Hong Kong, South Eastern Asia, India, the Middle East and Africa. Previously, he served as Boehringer Ingelheim’s Vice President, Head of Medicine Group (covering 9 functional groups in medicine) of Greater China. Prior to Boehringer Ingelheim, Dr. Chen served as director, Clinical research & development organization of Wyeth Asia Pacific, also the global medical lead for clinical development of chronic pain & anti-infection. Dr. Chen received his Medical Degree from Nanjing Medical University.